253 - POST-CANCER THERAPY CARDIOVASCULAR SURVEILLANCE AND MANAGMENT - THE CARDIOLOGIST'S ROLE, WHAT SHOULD WE DO AND WHEN?

Co-Chair(s)

• 

  Fernando Rivera-Theurel, MD, MSc

  Assistant Professor, Clinitian Investigator
  University Of Toronto
  University of Toronto
• IS

  Igal Sebag, MD, FRCPC, FACC, FASE (he/him/his)

  Professor
  CSE
  McGill University

Panelist(s)

• 

  Margot Davis, MD SM FRCPC FCCS (she/her/hers)

  Cardiologist
  University of British Columbia
  University of British Columbia
• AD

  Ahmad Didi, M.D
• ME

  Malak El-Rayes, M.D. FRCP

  Cardiologist, CSSS de Laval
  CCON
  University of Montreal
• 

  Darryl Leong, MBBS (Hons) MPH M.Biostat PhD FRACP FESC

  Director of the Cardio-Oncology Program at Hamilton Health Sciences
  CCON
  McMaster University
• MR

  Moira Rushton, MD MPH
• GS

  Guillaume St Pierre, M.D., F.R.C.P.C.

Presenter(s)

• EG

  Enrique Gonzalez, M.D.
• CP

  Cristina Pop, M.D.
• JS

  Jonathan Sen, MBBS, PhD, FRACP

Early Career(s)

• CY

  Christopher Yu, MBBS, PhD

Trainee(s)

• EG

  Enrique Gonzalez, M.D.
• CP

  Cristina Pop, M.D.
• JS

  Jonathan Sen, MBBS, PhD, FRACP

Moderator (required)(s)

• 

  Fernando Rivera-Theurel, MD, MSc

  Assistant Professor, Clinitian Investigator
  University Of Toronto
  University of Toronto
• DT

  Dinesh Thavendiranathan, MD, SM, FRCPC, FASE

  Cardiologist
  CCON
  University of Toronto

Planning Committee Member(s)

• HA

  Husam Abdel-Qadir, MD, PhD

  Associate Professor, Department of Medicine and Institute of Health Policy Management and Evaluation
  University of Toronto
  Women's College Hospital, University Health Network, University of Toronto
• CB

  Christine Brezden-Masley, MD

  Medical Director, Cancer Program
  Mount Sinai Hospital
  University of Toronto
• MN

  Michelle Nadler, M.D., MsC

  Assistant Professor, University of Toronto
  CCON
• CY

  Christopher Yu, MBBS, PhD
• AZ

  Amna Zafar, M.D., F.R.C.P.C.

  Cardiologist
  Mount Sinai Hospital

Workshop Description: This workshop will involve a case-based discussion regarding post-cancer therapy surveillance and management of patients with breast, prostate cancer, and lung cancer. These cancers are chosen as breast and prostate cancer are the most common cancers in women and men, respectively, and lung cancer is the most common cancer with pre-existing CVD and at highest risk of new diagnosis of CVD during/post therapy. A 7-minute case presentation will be followed by an 11-minute discussion led by a panel of experts, with interaction with the audience. The session will focus on who needs surveillance, who should perform surveillance, strategies targeted for therapies, and a multidisciplinary approach to managing cardiovascular disease. The session will close with the key take-home points for the audience.